Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Non-Current Assets (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of Non-Current Assets data on record, last reported at $25.5 million in Q3 2025.

  • For Q3 2025, Non-Current Assets rose 257.54% year-over-year to $25.5 million; the TTM value through Sep 2025 reached $49.5 million, up 61.64%, while the annual FY2024 figure was $7.1 million, 9.94% down from the prior year.
  • Non-Current Assets reached $25.5 million in Q3 2025 per CAPR's latest filing, up from $9.4 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $25.5 million in Q3 2025 and bottomed at $928489.0 in Q1 2021.
  • Average Non-Current Assets over 5 years is $7.1 million, with a median of $7.1 million recorded in 2024.
  • Peak YoY movement for Non-Current Assets: soared 469.5% in 2022, then dropped 9.94% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $4.9 million in 2021, then skyrocketed by 47.26% to $7.2 million in 2022, then increased by 9.33% to $7.9 million in 2023, then dropped by 9.94% to $7.1 million in 2024, then skyrocketed by 259.18% to $25.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $25.5 million in Q3 2025, $9.4 million in Q2 2025, and $7.5 million in Q1 2025.